FIELD: immunology.
SUBSTANCE: what is presented is a chimeric antigenic receptor for myeloma kappa antigen (KMA), a genetically modified T cell, a method for producing a genetically modified T cell, using a genetically modified T cell.
EFFECT: present invention can find further application in therapy of KMA-expressing malignant growths.
20 cl, 23 dwg, 5 ex
| Title | Year | Author | Number |
|---|---|---|---|
| MUC16-SPECIFIC CHIMERIC ANTIGEN RECEPTORS AND THEIR USE | 2019 |
|
RU2795198C2 |
| CHIMERIC ANTIGENE RECEPTOR | 2019 |
|
RU2810092C2 |
| CHIMERIC ANTIGENE RECEPTORS TARGETTING FLT3 | 2018 |
|
RU2820859C2 |
| CHIMERIC ANTIGEN RECEPTORS TARGETING CD70 | 2019 |
|
RU2801824C2 |
| CHIMERIC ANTIGEN RECEPTOR T-CELLS (CAR-T) FOR CANCER TREATMENT | 2019 |
|
RU2811466C2 |
| ISOLATED ALTERNATIVE INTRACELLULAR SIGNALLING DOMAIN OF CHIMERIC ANTIGEN RECEPTOR AND CHIMERIC ANTIGEN RECEPTOR INCLUDING IT | 2019 |
|
RU2742000C2 |
| CHIMERIC ANTIGEN RECEPTOR | 2018 |
|
RU2770002C2 |
| CHIMERIC ANTIGENIC RECEPTORS AIMED AT ANTIGEN OF AGING OF B CELLS, AND THEIR APPLICATION | 2015 |
|
RU2761632C2 |
| CHIMERIC ANTIGENIC RECEPTORS TO BCMA | 2015 |
|
RU2747457C2 |
| ANTI-CLL1-SPECIFIC SINGLE-CHAIN CHIMERIC ANTIGENIC RECEPTORS (SCCAR) FOR CANCER IMMUNOTHERAPY | 2016 |
|
RU2731543C2 |
